CNS Pharmaceuticals, Inc. (CNSP)

CNS Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	13.05	6.46	0.55	10.06	5	14.04
Cash & Short-Term Investments	13.05	6.46	0.55	10.06	5	14.04
Cash Growth	1500.49%	1077.53%	-94.54%	100.93%	-64.35%	93.88%
Other Receivables	-	0.88	-	-	-	-
Receivables	-	0.88	-	-	-	-
Prepaid Expenses	0.65	1.29	0.84	2.51	2.47	1.46
Other Current Assets	0.02	0.02	0.2	-	-	-
Total Current Assets	13.72	8.66	1.59	12.56	7.48	15.5
Property, Plant & Equipment	0	0.01	0	0.01	0.02	0.02
Long-Term Deferred Charges	-	-	-	-	0.33	0.33
Other Long-Term Assets	0.02	0.04	0.1	0.48	0.93	-
Total Assets	13.75	8.7	1.7	13.05	8.76	15.85
Accounts Payable	2.57	2.2	5.83	4.51	1.98	0.95
Accrued Expenses	-	-	-	-	0.22	0.52
Short-Term Debt	0.21	0.33	0.3	0.41	0.39	0.44
Total Current Liabilities	2.78	2.52	6.13	4.92	2.59	1.91
Total Liabilities	2.78	2.52	6.13	4.92	2.59	1.91
Common Stock	0	0	0	0	0	0.02
Additional Paid-In Capital	99.69	90.6	65.13	58.85	41.6	34.87
Retained Earnings	-88.73	-84.42	-69.57	-50.72	-35.44	-20.95
Shareholders' Equity	10.97	6.18	-4.43	8.13	6.16	13.95
Total Liabilities & Equity	13.75	8.7	1.7	13.05	8.76	15.85
Total Debt	0.21	0.33	0.3	0.41	0.39	0.44
Net Cash (Debt)	12.84	6.14	0.25	9.65	4.62	13.6
Net Cash Growth	2031.95%	2374.76%	-97.43%	108.92%	-66.05%	87.81%
Net Cash Per Share	12.08	16.05	-	-	-	-
Filing Date Shares Outstanding	5.46	2.94	-	-	-	-
Total Common Shares Outstanding	2.94	1.41	-	-	-	-
Working Capital	10.94	6.13	-4.54	7.64	4.88	13.59
Book Value Per Share	3.73	4.37	-	-	-	-
Tangible Book Value	10.97	6.18	-4.43	8.13	6.16	13.95
Tangible Book Value Per Share	3.73	4.37	-	-	-	-

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q